What Happened?

On January 8, 2026 Beta Bionics reported an unexpected miss to new iLet patient starts.

On this, Beta Bionics shares fell $11.85 or 37.04%, to close at $20.14 per share on January 9, 2026, thereby injuring investors.

Then, on January 30, 2026, Beta Bionics’ disclosed it had received a warning letter from the FDA related to a Form 483 (inspectional observations), including issues beyond mere complaint handling.

On this, Beta Bionics shares fell $0.96, or 6.5%, to close at $13.83 per share on January 30, 2026.

Finally, on February 24, 2026, the FDA publicly released a warning letter detailing a litany of violations and the Company’s failure to correct them. The warning letter made clear that the Company’s prior interpretation of FDA reporting requirements had not been reasonable and had excluded numerous serious patient incidents that clearly should have been reported.

On this news, Beta Bionics, Inc. stock price fell $0.50 or 3.73%, to close at $12.89 on February 25, 2026, thereby injuring investors further.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants omitted mention of the FDA Form 483 and iLet’s underlying safety issues, including that the Form 483 identified over 18,000 complaints including numerous life-threatening hypoglycemic events that the Company had “failed to investigate,” or even report to the FDA, with no justification; (2) the Company’s statements assuring investors that its remediation efforts were advanced and the FDA’s issues were “very benign,” failed to accurately describe the scope and severity of the FDA’s observations which made remediation much more complex and extensive than Defendants indicated to investors; (3) that the Company “could have opened a CAPA and did not” was misleading where the FDA had in fact concluded that Beta Bionics had, without justification, failed to investigate clearly serious, life-threatening customer reports; and (4)  that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.